1. TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling.
TFAP2A knockdown inhibits cell growth by targeting HIF-1α signaling. Human nasopharyngeal carcinoma cells were transfected with the DOTAP-cholesterol–based TFAP2A siRNA nanoparticles (si-TFAP2A). At 72 hours after transfection, the effect of TFAP2A knockdown on cell viability (A) and the expression of TFAP2A, VEGF, PEDF, and HIF-1α mRNAs (B), and proteins (C) were detected by MTT, RT-PCR, and Western blot analysis, respectively. The amounts of VEGF and PEDF secretion in cell culture media were determined by ELISA, and the ratio of VEGF-to-PEDF was analyzed D, the cells treated with nonspecific scramble siRNA (si-NS) were used as the control groups. The data are presented as mean ± SD of 3 tests. *, P < 0.05, significant differences between the si-TFAP2A or si-HIF-1-treated groups and the control siRNA groups.
Dingbo Shi et al. Cancer Prev Res 2014;7:
©2014 by American Association for Cancer Research